A Randomized, Double Blind, Placebo-controlled Study to Investigate the Effect of a Probiotic Product on Acute Upper Respiratory Tract Infections (Common Cold) in Healthy Children
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Probi AB
- Enrollment
- 550
- Locations
- 1
- Primary Endpoint
- Severity of acute upper respiratory tract infections (common cold), by means of the validated Canadian Acute Respiratory Illness and Flu Scale (CARIFS) questionnaire (total sum score), during 12 weeks of daily intake of either Probi Defendum® or placebo.
Study Overview
Brief Summary
The aim of the present study is to test the efficacy of the combination of two probiotic bacteria in reducing the severity of upper respiratory tract infections (common cold) in healthy children attending day care or school. The probiotic bacteria used are Lactobacillus plantarum strain DSM 15312 and Lactobacillus paracasei DSM 13434 at a total dose of 1 x 10^9 CFU/tablet and day and will be consumed for a period of 12 weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 3 Years to 7 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Parents / legal guardians signed written informed consent to participate in the study.
- •Healthy children (male and female) aged 3 to 7 years old (inclusive) at enrollment.
- •Children attending day care center or school.
- •No consumption of commercial products containing probiotics during the whole study period.
- •Children not being intensive consumers of regular yoghurts (no more than one 125 g serving per day).
- •Ability of the parents / legal guardians (in the Investigator's opinion) to comprehend the full nature and purpose of the study.
- •Parents' / legal guardians' consent to the study and willing to comply with all its procedures.
Exclusion Criteria
- •Children presenting one or more of the following criteria will not be eligible to enter the study.
- •Flu vaccine administration within the last 3 months prior to enrollment.
- •Use of antibiotics within the last 30 days prior to enrollment.
- •Acute infection or fever at enrollment.
- •Any congenital or chronic disease that in the opinion of the investigator would adversely affect the results of the study.
- •Any kind of immunodeficiency or allergy (including known food allergy).
- •Subjects with known hypersensitivity or allergy to any component of the study products.
- •Significant illness within the 2 weeks prior to the enrollment or any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study.
- •Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study.
Arms & Interventions
Probi Defendum
Dietary supplement (tablet) with probiotics
Intervention: Probi Defendum (Dietary Supplement)
Placebo
Dietary supplement (tablet) without probiotics
Intervention: Placebo (Dietary Supplement)
Outcomes
Primary Outcomes
Severity of acute upper respiratory tract infections (common cold), by means of the validated Canadian Acute Respiratory Illness and Flu Scale (CARIFS) questionnaire (total sum score), during 12 weeks of daily intake of either Probi Defendum® or placebo.
Time Frame: 12 weeks
Secondary Outcomes
- Incidence of common cold episodes(12 weeks)
- Duration of common cold episodes(12 weeks)
- Number of common cold episodes(12 weeks)